Device tax, sluggish sales weigh on Boston Scientific, analysts say

July 15, 2013 by Arezu Sarvestani

Analysts at Fitch Ratings affirm Boston Scientific's BBB- rating, warning that efforts to cut costs and launch higher-margin products won't quite make up for sluggish sales and the impact of the medical device tax.

Boston Scientific logo

Analysts at Fitch Ratings affirmed a BBB- rating on Boston Scientific (NYSE:BSX), predicting that cost-control efforts and new product launches won't be enough to make up for sluggish sales and the effect of the 2.3% medical device tax.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.